LU92939I2 - Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable - Google Patents
Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable Download PDFInfo
- Publication number
- LU92939I2 LU92939I2 LU92939C LU92939C LU92939I2 LU 92939 I2 LU92939 I2 LU 92939I2 LU 92939 C LU92939 C LU 92939C LU 92939 C LU92939 C LU 92939C LU 92939 I2 LU92939 I2 LU 92939I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- isavuconazonium
- salt
- isavuconbazole
- sulphate
- hydrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99121694 | 1999-11-02 | ||
| EP00992946A EP1280795B1 (en) | 1999-11-02 | 2000-10-25 | N-substituted carbamoyloxyalkyl-azolium derivatives |
| PCT/EP2000/010524 WO2001032652A2 (en) | 1999-11-02 | 2000-10-25 | N-substituted carbamoyloxyalkyl-azolium derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU92939I2 true LU92939I2 (fr) | 2016-03-07 |
Family
ID=8239312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92939C LU92939I2 (fr) | 1999-11-02 | 2016-01-06 | Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1280795B1 (nl) |
| JP (1) | JP3787307B2 (nl) |
| KR (1) | KR100449797B1 (nl) |
| CN (1) | CN1185230C (nl) |
| AR (1) | AR029403A1 (nl) |
| AT (1) | ATE291575T1 (nl) |
| AU (1) | AU777859B2 (nl) |
| BE (1) | BE2016C007I2 (nl) |
| BR (1) | BRPI0015254C1 (nl) |
| CA (2) | CA2680292C (nl) |
| CY (1) | CY2016002I2 (nl) |
| DE (1) | DE60018989T2 (nl) |
| DK (1) | DK1280795T3 (nl) |
| ES (1) | ES2238341T3 (nl) |
| FR (1) | FR15C0096I2 (nl) |
| LU (1) | LU92939I2 (nl) |
| MX (1) | MXPA02004145A (nl) |
| NL (1) | NL300791I1 (nl) |
| PT (1) | PT1280795E (nl) |
| TR (1) | TR200201205T2 (nl) |
| WO (1) | WO2001032652A2 (nl) |
| ZA (1) | ZA200203003B (nl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| MX2010001730A (es) | 2007-08-21 | 2010-03-10 | Basilea Pharmaceutica Ag | Composicion antimicotica. |
| US9907812B2 (en) | 2011-06-22 | 2018-03-06 | Vyome Biosciences Pvt. Ltd. | Conjugate-based antifungal and antibacterial prodrugs |
| NZ714817A (en) | 2013-06-04 | 2017-07-28 | Vyome Biosciences Pvt Ltd | Coated particles and compositions comprising same |
| CN104230894B (zh) * | 2013-06-06 | 2016-08-24 | 南京华威医药科技开发有限公司 | 三唑类化合物 |
| JP6684810B2 (ja) * | 2014-12-30 | 2020-04-22 | ダウ アグロサイエンシィズ エルエルシー | 殺真菌剤としてのピコリンアミド化合物の使用 |
| CN106032356B (zh) * | 2015-03-13 | 2018-09-14 | 江苏正大丰海制药有限公司 | 一种[n-甲基-吡啶-2-基]氨基甲酸-1-氯乙酯的制备方法 |
| CN104974143A (zh) * | 2015-05-12 | 2015-10-14 | 深圳致君制药有限公司 | 一种季铵盐类化合物、其制备方法以及用途 |
| CN106467534B (zh) * | 2015-08-17 | 2019-10-11 | 江苏奥赛康药业有限公司 | 一种硫酸艾沙康唑鎓化合物及其药物组合物 |
| CN106467519B (zh) * | 2015-08-17 | 2019-08-13 | 南京华威医药科技集团有限公司 | 一种水溶性三唑化合物 |
| CN106565699B (zh) * | 2015-10-10 | 2019-07-26 | 江苏正大丰海制药有限公司 | 一种艾沙康唑硫酸盐晶体及其制备方法 |
| WO2018067702A1 (en) | 2016-10-04 | 2018-04-12 | Massachusetts Institute Of Technology | Bottlebrush copolymers and uses thereof |
| WO2018149359A1 (zh) * | 2017-02-17 | 2018-08-23 | 武汉朗来科技发展有限公司 | 三氮唑抗菌衍生物、其药物组合物和用途 |
| CN106916152B (zh) * | 2017-04-27 | 2019-09-17 | 扬子江药业集团有限公司 | 氧化还原反应制备艾沙康唑鎓单硫酸盐的方法 |
| WO2019006425A1 (en) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | IMAGING AGENTS OF BRUSH ARRAY STAR POLYMERS AND USES THEREOF |
| EP3645530A2 (en) | 2017-06-30 | 2020-05-06 | Massachusetts Institute of Technology | Branched multi-functional macromonomers and related polymers and uses thereof |
| US10368502B2 (en) | 2017-09-25 | 2019-08-06 | Multiple Energy Technologies Llc | Bioceramic and carbon-based hydroponic systems, methods and devices |
| CN110317165A (zh) * | 2018-03-28 | 2019-10-11 | 上海医药工业研究院 | 一种药物中间体2-甲胺基-3-吡啶甲醇的制备方法 |
| CN110551064B (zh) * | 2018-06-01 | 2021-01-01 | 重庆世森医药科技有限公司 | 艾沙康唑硫酸酯及其中间体的制备方法 |
| WO2020025553A1 (en) | 2018-08-01 | 2020-02-06 | Basilea Pharmaceutica International AG | Methods for purifying isavuconazonium sulfate |
| US10988491B2 (en) | 2018-08-17 | 2021-04-27 | Massachusetts Institute Of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| CN110128420A (zh) * | 2019-05-08 | 2019-08-16 | 阴启明 | 硫酸氢根/硫酸根型阴离子交换技术制备艾沙康唑鎓单硫酸盐的方法 |
| EP4021576A1 (en) | 2019-08-26 | 2022-07-06 | Synthon B.V. | Isavuconazonium salts and process for preparing thereof |
| AU2020368453A1 (en) * | 2019-10-16 | 2022-04-21 | Massachusetts Institute Of Technology | Brush prodrugs and uses thereof |
| JP7454905B2 (ja) * | 2021-09-28 | 2024-03-25 | 旭化成ファーマ株式会社 | 有効成分であるイサブコナゾール又はそのプロドラッグを含有する真菌症治療及び／又は予防剤 |
| JP2023049010A (ja) | 2021-09-28 | 2023-04-07 | 旭化成ファーマ株式会社 | エアベント付き輸液フィルタを備える点滴静脈投与用輸液セット |
| EP4289840A1 (en) | 2022-06-07 | 2023-12-13 | Zaklady Farmaceutyczne Polpharma S.A. | A process for preparing isavuconazonium sulfate |
| WO2024094329A1 (en) | 2022-11-01 | 2024-05-10 | Basilea Pharmaceutica International Ag, Allschwil | Blister-packaged capsule preparation containing isavuconazonium sulfate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407129B1 (en) * | 1997-03-31 | 2002-06-18 | Takeda Chemical Industries, Ltd. | Azole compounds, their production and their use |
| JP3108997B2 (ja) * | 1997-03-31 | 2000-11-13 | 武田薬品工業株式会社 | アゾール化合物、その製造法および用途 |
| AU2931399A (en) * | 1998-03-06 | 1999-09-20 | F. Hoffmann-La Roche Ag | 3-(4-(4-cyanophenyl)thiazol-2-y))-1-(1h-1,2,4-triazol-1-yl) -butan-2-ol derivatives having antifungal activity |
-
2000
- 2000-10-25 CN CNB008153299A patent/CN1185230C/zh not_active Expired - Lifetime
- 2000-10-25 KR KR10-2002-7005574A patent/KR100449797B1/ko active Protection Beyond IP Right Term
- 2000-10-25 PT PT00992946T patent/PT1280795E/pt unknown
- 2000-10-25 WO PCT/EP2000/010524 patent/WO2001032652A2/en active Search and Examination
- 2000-10-25 DE DE60018989T patent/DE60018989T2/de not_active Expired - Lifetime
- 2000-10-25 CA CA2680292A patent/CA2680292C/en not_active Expired - Lifetime
- 2000-10-25 AU AU28352/01A patent/AU777859B2/en active Active
- 2000-10-25 DK DK00992946T patent/DK1280795T3/da active
- 2000-10-25 AT AT00992946T patent/ATE291575T1/de active
- 2000-10-25 ES ES00992946T patent/ES2238341T3/es not_active Expired - Lifetime
- 2000-10-25 CA CA002388320A patent/CA2388320C/en not_active Expired - Lifetime
- 2000-10-25 MX MXPA02004145A patent/MXPA02004145A/es active IP Right Grant
- 2000-10-25 BR BRPI0015254A patent/BRPI0015254C1/pt not_active IP Right Cessation
- 2000-10-25 EP EP00992946A patent/EP1280795B1/en not_active Expired - Lifetime
- 2000-10-25 TR TR2002/01205T patent/TR200201205T2/xx unknown
- 2000-10-25 JP JP2001534803A patent/JP3787307B2/ja not_active Expired - Lifetime
- 2000-10-31 AR ARP000105739A patent/AR029403A1/es active IP Right Grant
-
2002
- 2002-04-16 ZA ZA200203003A patent/ZA200203003B/xx unknown
-
2015
- 2015-12-29 FR FR15C0096C patent/FR15C0096I2/fr active Active
-
2016
- 2016-01-06 LU LU92939C patent/LU92939I2/xx unknown
- 2016-01-26 NL NL300791C patent/NL300791I1/nl unknown
- 2016-02-03 CY CY2016002C patent/CY2016002I2/el unknown
- 2016-02-26 BE BE2016C007C patent/BE2016C007I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92939I2 (fr) | Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable | |
| LU91681I2 (fr) | "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)" | |
| LU91372I2 (fr) | Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo) | |
| LU91442I2 (fr) | "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate" | |
| PT2264018E (pt) | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer | |
| LU88842I2 (fr) | Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol | |
| LU92428I2 (fr) | Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable | |
| LU92397I2 (fr) | Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable | |
| MA26641A1 (fr) | Utilisation de conjuges pef-ifn- & en association avec la ribavirine pour la fabrication de medicaments | |
| IS1812B (is) | Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra | |
| IL164555A0 (en) | 4-'7-Halo-2-quino (xa-)linyloxy! phenoxy-propionicacid derivatives as antineoplastic agents | |
| FR2862279B1 (fr) | Ballon gonflable a facettes pour l'evenementiel | |
| IL149607A0 (en) | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3 benzazocines and the use thereof as medicaments | |
| Boyne | The Montreal Metro: reflections of a city | |
| TH52440EX (th) | " ไฟฉาย " | |
| TH59434EX (th) | ขวด | |
| GB9910151D0 (en) | Multivalent agents for use in the treatmnet of mitochondrial diseases | |
| TH50938EX (th) | เครื่องผลิตน้ำประปาสำเร็จรูป | |
| ZA200001464B (en) | 142b/124 blowing agent blends. | |
| TH47149EX (th) | ปากกา | |
| TH54234EX (th) | ปากกา | |
| SE9903774D0 (sv) | Hålslag kongerens | |
| TH44135EX (th) | ที่จับกระดาษ | |
| FR2797766B1 (fr) | Nouvelles formes topiques a consistance pateuse sous forme d'un gel distribue en doses | |
| TH41844EX (th) | เครื่องพิมพ์ |